Exela Technologies, Inc. Reports Fourth Quarter and Full Year 2017 Results; Achieves Full Year Guidance for Pro Forma Revenue and Adjusted EBITDA; Sets 2018 Revenue Guidance of 4%-6%, Above Previous Long-Term Guidance


2017 GAAP Revenue of $1.152 billion, an increase of 46% 
2017 Pro Forma Revenue of $1.456 billion, an increase of 9% 
2017 GAAP Net Loss of ($204) million including charges totaling $221 million

IRVING, Texas, March 15, 2018 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ:XELA), one of the largest global providers of platforms for Business Process Automation (“BPA”), announced today its financial results for the fourth quarter and year-end for the year ended December 31, 2017. 

“I’m pleased with our operational and financial results highlighted by 2017 pro forma revenue growth of 9% and meeting our full-year 2017 guidance for pro forma revenue and Adjusted EBITDA. Revenue from our top 100 customers grew 14% year-over-year.

As I look to the future we have numerous opportunities for growth, by leveraging our scale, experience and references in business process automation and in industry-specific and industry-agnostic enterprise software solutions.

To best position the Company for long term shareholder value, and to increase our profitability, our strategy includes, increasing awareness of our Company’s solutions in the market, and accelerating investments in people and technologies,” said Ronald Cogburn, Chief Executive Officer.

Financial information contained in this press release is presented pro forma for the business combination of Quinpario Acquisition Corp. 2, SourceHOV Holdings, Inc. (“SourceHOV”) and Novitex Holdings, Inc. (“Novitex”), which closed on July 12, 2017. The primary pro forma adjustment is to include the results of Novitex for the period January 1, 2017 to July 12, 2017. For more information, please refer to the reconciliation of reported to pro forma financial results contained in the Schedules of this release.

Full-Year 2017 Pro Forma Financial Highlights

  • Revenue: $1.456 billion, an increase of 9.2% from $1.331 billion in 2016. Information & Transaction Processing Solutions (“ITPS”) revenue was $1.131 billion, an increase of 15.0%. Healthcare Solutions (“HS”) revenue totaled $233.6 million, a decrease of 5.6%. Legal and Loss Prevention Services (“LLPS”) revenue totaled $91.6 million in 2017, a decrease of 9.0%.
  • 100 customers represent ~60% of total revenue, up 14%
  • 6 customers over $25 million in annual revenue and over approximately 200 customers with more than $1 million in annual revenue.
  • Low concentration with the largest customer representing 6% of total revenue.
  • Revenue per full-time employee increased to $66k from $56k.
     
  • Adjusted EBITDA: $245.2 million, representing an Adjusted EBITDA margin of 16.9%, compared with Adjusted EBITDA of $248.5 million and 18.6% margin in 2016.
     
  • Further Adjusted EBITDA: $346.8 million, representing a Further Adjusted EBITDA margin of 23.8%, compared with Further Adjusted EBITDA of $349.9 million and 26.2% margin in 2016. The year-over-year decrease in Further Adjusted EBITDA was primarily driven by higher ramp-up costs associated with new ITPS client contracts, investments in the Company’s revenue growth initiatives, and higher public company costs, partially offset by cost savings initiatives of which over $40 million was delivered in 2017.
     
  • Capital Expenditures: 2.9% of 2017 revenue compared to 3.9% of 2016 revenue 

             
Balance Sheet and Liquidity
             

  • Balance Sheet and Liquidity: At December 31, 2017, Exela’s total liquidity was $141 million and total net debt was $1.345 billion.  The Company had cash of $62 million, of which $23 million is segregated for customer use and a $100 million revolving credit facility, which was undrawn, but net of $21 million in stand-by letters of credit, giving the Company $79 million at December 31, 2017 available for borrowing.   
     
  • Net Leverage Ratio: 3.88x

Fourth Quarter Ended December 31, 2017 Pro Forma Financial Highlights

  • Revenue: Actual revenue of $386.3 million, an increase of 9.6% from $352.5 million in the fourth quarter of 2016, and an increase of 7.8% from $358.2 million in the third quarter of 2017. Refer to pro forma revenue reconciliation for third quarter of 2017 and fourth quarter of 2016. All three segments grew revenue on a year-over year basis. ITPS revenue was $301.5 million, an increase of 11.2% year-over- year, driven primarily by increased volumes and expansion of services within existing customers. HS revenue was $60.1 million, an increase of 2.5%. LLPS revenue was $24.7 million, an increase of 8.3%.
     
  • Net Loss: ($58.7) million and includes an impairment charge of approximately ($69.4) million. Net loss for the fourth quarter of 2016 totaled ($19.9) million. Excluding the impairment charge, the company would have reported a net income of $10.7 million for the fourth quarter of 2017.
     
  • Adjusted EBITDA: $62.7 million, representing a margin of 16.3%, compared with Adjusted EBITDA of $64.7 million and margin of 18.4% in the fourth quarter of 2016. The year-over-year decrease in fourth quarter 2017 Adjusted EBITDA was primarily driven by higher ramp-up costs associated with new ITPS client contracts, investments in the Company’s revenue growth initiatives, and higher public company costs.
     
  • Stock buy-back: purchased 49,300 shares to partially fund the long-term incentive plan.

             
             
Outlook
            2018

  • Initial 2018 revenue guidance is in the range of $1.510 billion - $1.540 billion or of 4% - 6%, exceeding the Company’s previous long-term guidance of 3% - 4% growth based on our visibility heading into 2018
  • Adjusted EBITDA guidance – in the range of $290- $310 million or growth of 18% - 26%, representing a 19% - 20% margin for 2018
  • Further Adjusted EBITDA guidance – in the range of $330- $355 million or a margin of 22% - 23%
  • Guidance includes delivering $40 - $45 million in savings during 2018 with remaining during 2019

            Long-term

  • Revenue growth in the range of 3%-4%
  • Further Adjusted EBITDA margin guidance in the range of 22% - 23%
  • Guidance is based on constant-currency

The above outlook is based on 2017 pro forma results. Reconciliations are available in the attached tables.

Earnings Conference Call and Audio Webcast

Exela will host a conference call to discuss its fourth quarter 2017 financial results today at 5:00 p.m. EDT.  To access this call, dial 800-860-2442 or +412-858-4600.  A replay of this conference call will be available through March 22, 2018 at 877-344-7529 or +412-317-0088 (international).  The replay passcode is 10116940.  A live webcast of this conference call will be available on the “Investors” page of the Company’s website (www.exelatech.com). A supplemental slide presentation that accompanies this call and webcast can be found on the investor relations website (http://investors.exelatech.com/) and will remain available after the call.  Exela has also posted additional historical financial information regarding SourceHOV Holdings, Inc. and Novitex Holdings, Inc. on a combined basis to its investor relations website, (http://investors.exelatech.com).

About Exela:  Embracing complexity. Delivering simplicity. Exela Technologies, Inc. (“Exela”) is a global business process automation ("BPA") leader combining industry-specific and industry-agnostic enterprise software and solutions with decades of experience. Our BPA suite of solutions are deployed in banking, healthcare, insurance and other industries to support mission-critical environments. Exela is a leader in workflow automation, attended and un-attended cognitive automation, digital mailrooms, print communications, and payment processing with deployments across the globe.

Exela partners with customers to improve user experience and quality through operational efficiency. Exela serves over 3,500 customers across more than 50 countries, through a secure, cloud-enabled global delivery model. We are 22,000 employees strong at nearly 1,200 onsite client facilities and 150 delivery centers located throughout the Americas, Europe and Asia. Our client list includes 60% of the Fortune® 100, along with many of the world’s largest retail chains, banks, law firms, healthcare insurance payers and providers and telecom companies.

Follow Exela on Twitter: https://twitter.com/exelatech
Follow Exela on LinkedIn: https://www.linkedin.com/company/11174620/

About Non-GAAP Financial Measures: This earnings release presents certain non-GAAP financial measures including EBITDA, Adjusted EBITDA, Further Adjusted EBITDA, each of which is a financial measure that is not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). We believe that the presentation of these non-GAAP financial measures will provide useful information to investors in assessing our financial performance, results of operations and liquidity. We believe these non-GAAP measures allow investors to better understand the trends in our business and to better understand and compare our results. Our board of directors and management use EBITDA, Adjusted EBITDA, and Further Adjusted EBITDA to assess our financial performance, because it allows them to compare our operating performance on a consistent basis across periods by removing the effects of our capital structure (such as varying levels of debt and interest expense, as well as transaction costs resulting from the business combination and other such capital markets based activities. Adjusted EBITDA and Further Adjusted EBITDA also seek to remove the effects of integration and related costs to achieve the savings, any expected reduction in operating expenses due to the business combination, asset base (such as depreciation and amortization) and other similar non-routine items outside the control of our management team. The Company does not consider these non-GAAP measures in isolation or as an alternative to liquidity or financial measures determined in accordance with GAAP. A limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures and therefore the basis of presentation for these measures may not be comparable to similarly-titled measures used by other companies. These non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP. Net loss is the GAAP measure most directly comparable our non-GAAP measures. For reconciliation of the comparable GAAP measures to these non-GAAP financial measures, see the schedules to this release. Optimization & restructuring expenses and merger adjustments are primarily related to the implementation of strategic actions and initiatives related to the business combination completed on July 12, 2017. All of these costs are variable and dependent upon the nature of the actions being implemented and can vary significantly driven by business needs. Accordingly, due to that significant variability, we exclude these charges since we do not believe they truly reflect our past, current or future operating performance.

Forward-Looking Statements: Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation  Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may”, “should”, “would”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “continue”, “future”, “will”, “expect”, “outlook” or other similar words, phrases or expressions. These forward-looking statements include statements regarding our  industry, future events, the estimated or anticipated future results and benefits of the recently consummated transaction between Exela Technologies, Inc., SourceHOV Holdings, Inc., and  Novitex Holdings, Inc. (including the related transactions, the “Business Combination”), future opportunities for the combined company, and other statements that are not historical  facts. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding Exela’s businesses, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Exela operates and general financial, economic, regulatory and political conditions affecting the industries in which Exela operates; changes in taxes, governmental laws, and regulations; competitive product and pricing activity; failure to realize the anticipated benefits of the Business Combination, including as a result of a delay or difficulty in integrating the businesses of SourceHOV and Novitex or the inability to realize the expected amount and timing of cost savings and operating synergies of the Business Combination; and those factors discussed under the heading “Risk Factors” in Exela’s Proxy Statement dated June 26, 2017 (the “Proxy Statement”) filed with the Securities and Exchange Commission (“SEC”). In addition, forward-looking statements provide Exela’s expectations, plans or forecasts of future events and views as of the date of this communication. Exela anticipates that subsequent events and developments will cause Exela’s assessments to change. These forward-looking statements should not be relied upon as representing Exela’s assessments as of any date subsequent to the date of this presentation.

 
Exela Technologies
Condensed Consolidated Balance Sheet (Unaudited)
 
  December 31,
  2017 2016
Assets    
Current assets    
Cash and cash equivalents $  39,000  $  8,361
Restricted cash    42,489    25,892
Accounts receivable, net of allowance for doubtful accounts of $3,725 and $3,200, respectively   229,704  138,421
Inventories, net   11,922  11,195
Prepaid expenses and other current assets   24,596    12,202
Total current assets 347,711  196,071
     
Property, plant and equipment, net    132,908  81,600
Goodwill   747,325  373,291
Intangible assets, net    464,984    298,739
Deferred income tax assets   9,019    9,654
Other noncurrent assets   12,891  10,131
Total assets  $1,714,838   $969,486
     
Liabilities and Stockholders’ Equity (Deficit)    
Liabilities    
Current Liabilities    
Accounts payable  $  81,263   $  42,212
Related party payables   14,445    9,344
Income tax payable   3,612  1,031
Accrued liabilities    104,485    29,492
Accrued compensation and benefits   46,925  31,200
Customer deposits   31,656    18,729
Deferred revenue   12,709  17,235
Obligation for claim payment    42,489    25,892
Current portion of capital lease obligations   15,611  6,507
Current portion of long-term debt   20,565    55,833
Total current liabilities 373,760  237,475
     
Long-term debt, net of current maturities    1,276,094  983,502
Capital lease obligations, net of current maturities    25,958    18,439
Pension liability   25,496  28,712
Deferred income tax liabilities   5,362     26,223
Long-term income tax liability   3,470  3,063
Other long-term liabilities   14,704  11,973
Total liabilities   1,724,844    1,309,387
Commitments and Contingencies    
Stockholders' equity (deficit)    
Common stock, par value of $0.0001 per share; 1,600,000,000 shares authorized; 150,578,451 shares issued and 150,529,151 shares outstanding at December 31, 2017 and 64,024,557 shares issued and outstanding at December 31, 2016   15    6
Preferred stock, par value of $0.0001 per share; 20,000,000 shares authorized; 6,194,233 shares issued and outstanding at December 31,2017 and no shares issued or outstanding at December 31, 2016   1    - 
Additional paid in capital   482,018  (57,395)
Less: common stock held in treasury, at cost; 49,300 shares at December 31, 2017 and no shares at December 31, 2016   (249) -
Equity based compensation   34,085    27,342
Accumulated deficit    (514,628) (293,968)
Accumulated other comprehensive loss:    
Foreign currency translation adjustment   (194) (3,547)
Unrealized pension actuarial losses, net of tax   (11,054) (12,339)
Total accumulated other comprehensive loss   (11,248)   (15,886)
     
Total stockholders' equity (deficit)   (10,006)   (339,901)
     
Total liabilities and stockholders' equity (deficit)  $1,714,838   $969,486
     


 
Exela Technologies
Condensed Consolidated Statements of Income (Loss) (Unaudited)
 
  Year ended December 31,
  2017 2016 2015
Revenue  $  1,152,324  $  789,926  $  805,232
Cost of revenue (exclusive of depreciation and amortization)  829,143   519,121   559,846
Selling, general and administrative expenses    220,955   130,437   120,691
Depreciation and amortization   98,890   79,639   75,408
Impairment of goodwill and other intangible assets   69,437   -   -
Related party expense   33,431   10,493   8,977
Operating income (loss)   (99,532)   50,236   40,310
       
Other expense (income), net:      
Interest expense, net   128,489   109,414   108,779
Loss on extinguishment of debt   35,512   -   -
Sundry expense, net   2,295   712   3,247
Other income, net   (1,297)   -   -
Net loss before income taxes   (264,531)   (59,890)   (71,716)
       
Income tax (expense) benefit   60,246   11,787   26,812
Net loss   (204,285)   (48,103)   (44,904)
Dividend equivalent on Series A Preferred Stock related to beneficial conversion feature   (16,375)   -   -
Cumulative dividends for Series A Preferred Stock   (2,489)   -   -
Net loss attributable to common stockholders  $  (223,149)  $  (48,103)  $  (44,904)
Earnings per share:   -  -
Basic and diluted  $  (2.08)  $  (0.75)  $  (0.70)
       
       



 
Exela Technologies
Condensed Consolidated Statements of Cash Flows (Unaudited)
 
  Year ended December 31,
  2017 2016 2015
Cash flows from operating activities      
Net loss  $  (204,285)  $  (48,103)  $  (44,904)
Adjustments to reconcile net loss      
Depreciation and amortization   98,890   79,639   75,408
Fees paid in stock   23,875   -   -
HGM Contract Termination Fee paid in stock   10,000   -   -
Original issue discount and debt issuance cost amortization   12,280   13,684   12,974
Loss on extinguishment of debt   35,512   -   -
Impairment of goodwill and other intangible assets   69,437   -   -
Provision (recovery) for doubtful accounts   500   756   1,105
Deferred income tax benefit   (66,723)   (15,729)   (27,177)
Share-based compensation expense   6,743   7,086   8,122
Foreign currency remeasurement   1,382   193   150
Gain on sale of Meridian   (588)   -   -
Loss on sale of property, plant and equipment   987   2,245   632
Fair value adjustment of swap derivative   (1,297)   -   -
Change in operating assets and liabilities, net of effect from acquisitions      
Accounts receivable   (4,832)   20,801   11,583
Prepaid expenses and other assets   2,628   4,969   892
Accounts payable and accrued liabilities   52,953   5,544   (28,644)
Related party payables   4,907   (2,427)   (2,703)
Net cash provided by operating activities   42,369   68,658   7,438
       
Cash flows from investing activities      
Purchases of property, plant and equipment   (14,440)   (7,926)   (10,669)
Additions to internally developed software   (7,843)   (13,017)   (3,279)
Additions to outsourcing contract costs   (10,992)   (14,636)   (7,882)
Cash paid for TransCentra purchase option    -   -   (12,810)
Cash acquired in Transcentra acquisition   -   3,351   -
Proceeds from sale of Meridian   4,582   -   -
Cash acquired in Quinpario reverse merger   91   -   -
Cash paid in Novitex acquisition, net of cash received   (423,428)   -   -
Other acquisitions, net of cash received   (369)    
Proceeds from sale of property, plant and equipment   25   626   208
Net cash used in investing activities   (452,374)   (31,602)   (34,432)
       
Cash flows from financing activities      
Change in bank overdraft   (210)   (1,331)   938
Proceeds from issuance of stock   204,417   -   -
Cash received from Quinpario   27,031   -   -
Repurchases of common stock   (249)   -   -
Proceeds from financing obligations   3,116   5,429   5,554
Contribution from shareholders   20,548   -   -
Proceeds from new credit facility   1,320,500   -   -
Retirement of previous credit facilities   (1,055,736)   -   -
Cash paid for debt issuance costs   (39,837)   -   -
Cash paid for equity issue costs   (149)   -   -
Borrowings from revolver and swing-line loan   72,600   53,700   157,400
Repayments from revolver and swing line loan   (72,500)   (53,200)   (108,800)
Principal payments on long-term obligations   (39,316)   (47,853)   (33,474)
Net cash provided by (used in) financing activities   440,215   (43,255)   21,618
       
Effect of exchange rates on cash   429   (2,059)   (672)
Net increase (decrease) in cash and cash equivalents    30,639   (8,258)   (6,048)
Cash and cash equivalents       
Beginning of period   8,361   16,619   22,667
End of period  $  39,000  $  8,361  $  16,619
       
Supplemental cash flow data:      
Income tax payments, net of refunds received  $  5,711  $  3,771  $  1,784
Interest paid   69,622   96,166   87,302
Noncash investing and financing activities:      
Assets acquired through capital lease arrangements    6,973   11,925   6,021
Leasehold improvements funded by lessor   146   5,186   665
Issuance of common stock as consideration for Novitex   244,800   -   -
Accrued capital expenditures   1,621   580   878
Dividend equivalent on Series A Preferred Stock  $  16,375  $  -  $  -
Liability assumed of Quinpario   4,672    
       


 
Exela Technologies
Schedule 1: Pro Forma 2016 vs. 2017 Financial Performance
 
($ in millions)
Pro Forma
FY 2017
Pro Forma
FY 2016 
 % Change
Revenue    
Information and Transaction Processing Solutions$1,131.0$983.3 15.0%
Healthcare Solutions233.6247.6 -5.6%
Legal and Loss Prevention Services91.6102.2 -10.4%
Total Revenue1,456.31,333.1 9.2%
     
Cost of revenue (exclusive of depreciation and amortization)1,079.9957.1  
Selling, general and administrative expenses (Incl related party)289.5190.8  
Depreciation and amortization119.5120.2  
Impairment of goodwill and other intangible assets 69.4  -   
Operating income (loss)(102.1)64.9  
     
Interest expense, net153.4157.3  
Loss / (Gain) on extinguishment of debt53.0(2.3)  
Sundry expense (income) & Other income, net1.1(1.6)  
Net loss before income taxes(309.6)(88.5)  
Income tax expense / (benefit)(67.2)(23.6)  
Net loss(242.4)(64.9)  
     
Depreciation and amortization119.5120.2  
Interest expense, net153.4157.3  
Income tax expense / (benefit)(67.2)(23.6)  
EBITDA(36.7)189.0  
Impairment of goodwill and other intangible assets69.4  -   
(Gain) / loss on extinguishment of debt53.0(2.3)  
Transaction and integration costs99.03.3  
Optimization and restructuring expenses47.936.0  
Non-cash charges, oversight & management fees12.622.5  
Adjusted EBITDA$245.2$248.5  
 16.8%18.6%  
     
     
Further Adjusted EBITDA$346.8$349.9 -0.9%
% Margin23.8%26.2%  
 
Note:  Pro Forma FY 2017 SG&A (Including related party) of $289.5 million includes non-routine transaction related expenses of $99.0 million. Refer to Further Adjusted EBITDA reconciliation.

(1) Financial results for Pro Forma FY 2016 do not include contribution from the TransCentra acquisition for the first nine months of the year since the transaction was closed on September 28, 2016.

(2) For additional information refer to Further Adjusted EBITDA Reconciliations



Exela Technologies
Schedule 2: Pro Forma Fourth Quarter 2016 vs. Fourth Quarter 2017 Financial Performance
    
($ in millions)
Q4 2017Pro Forma
Q4 2016
 
Revenue   
Information and Transaction Processing Solutions$301.5$271.0 
Healthcare Solutions60.158.6 
Legal and Loss Prevention Services24.722.8 
Total Revenue386.3352.5 
    
Cost of revenue (exclusive of depreciation and amortization)289.9256.0 
Selling, general and administrative expenses (Including related party)50.049.9 
Depreciation and amortization28.131.2 
Impairment of goodwill and other intangible assets 69.40.0 
Operating income (loss)(51.2)15.4 
    
Interest expense, net36.740.2 
Sundry expense (income) & Other income, net(2.0)0.4 
Net loss before income taxes(86.0)(25.3) 
Income tax expense / (benefit)(27.3)(5.3) 
Net loss(58.7)(19.9) 
    
Depreciation and amortization28.131.2 
Interest expense, net36.740.2 
Income tax expense / (benefit)(27.3)(5.3) 
EBITDA(21.1)46.1 
Impairment of goodwill and other intangible assets69.4  -  
Transaction and integration costs2.41.5 
Optimization and restructuring expenses11.010.0 
Non-cash charges, oversight & management fees1.07.1 
Adjusted EBITDA$62.7$64.7 
 16.2%18.4% 


Exela Technologies
Schedule 3: Adjusted EBITDA Reconciliation – Fourth Quarter 2016
 
      
As Reported
Q4 2016(1)
 Novitex
Q4 2016(1)
 Pro Forma
Q4 2016(1)
Net loss($14.7) ($5.3) ($19.9)
Taxes  (1.8)   (3.5)   (5.3)
Interest expense  27.7   12.5   40.2
Depreciation and amortization  21.2   10.0   31.2
EBITDA$32.4 $13.7 $46.1
Optimization and restructuring expenses  8.8   1.2   10.0
Transaction and integration costs  1.5   -   1.5
Non-cash charges  2.9   -   2.9
New contract setup  -   0.9   0.9
Oversight and management Fees  2.7   0.6   3.4
Adjusted EBITDA$48.3 $16.4 $64.7
      
 (1) Note: Net loss for the period is presented on the basis of the previous debt structure at the respective standalone companies. As of July 12th, 2017  the existing debt structures at respective Exela entities have been replaced with a new capital structure consisting of $350 Million Term Loan and $1.0 Billion Senior Secured Notes. 


 
 Exela Technologies
Schedule 4: Adjusted EBITDA Reconciliation – Fourth Quarter 2017
   
 As Reported
Q4 2017
Net loss ($58.7)
Taxes   (27.3)
Interest expense   36.7
Depreciation and amortization   28.1
EBITDA ($21.1)
Impairment of goodwill and other intangible assets   69.4
Optimization and restructuring expenses   11.0
Transaction and integration costs   2.4
Non-cash charges   2.3
New contract setup   - 
Oversight and management Fees   - 
(Gain) / loss on extinguishment of debt   - 
(Gain) / loss on derivative instruments   (1.3)
Adjusted EBITDA $62.7
   
   
   


   Exela Technologies
Schedule 5: Further Adjusted EBITDA Reconciliation – 2016
($ in millions)     
As Reported
FY 2016(1)
 Novitex
FY 2016
 Pro Forma
FY 2016(1)
Net loss($48.1) ($19.1) ($67.2)
Taxes  (11.8)   (11.8)   (23.6)
Interest expense  109.4   47.9   157.3
Depreciation and amortization  79.6   40.6   120.2
EBITDA$129.2 $57.6 $186.7
Optimization and restructuring expenses  7.6   28.4   36.0
Transaction and integration costs  18.8   (15.6)   3.3
Non-cash charges  9.8   -    9.8
New contract setup  -    5.3   5.3
Oversight and management Fees  7.8   1.9   9.7
(Gain) / loss on extinguishment of debt  -    (2.3)   (2.3)
(Gain) / loss on derivative instruments  -    -    - 
Impairment of goodwill and other intangible assets  -    -    - 
Adjusted EBITDA$173.2 $75.3 $248.5
Gain / (loss) on currency exchange  0.7   -    0.7
Combined merger adjustments      100.6
Further Adjusted EBITDA    $349.9
      
(1) Financial results as reported for FY 2016 and Pro Forma FY 2016 do not include contribution for the first nine months from the TransCentra acquisition which closed on September 28, 2016.
Note:  
- Net loss for the period January 1- July 12 is presented on the basis of the previous debt structure at the respective standalmpanies. As of July 12th, the existing debt structures at respective Exela entities have been replaced with a new capital structure consisting of $350 Million Term Loan and $1.0 Billion Senior Secured Notes.
- Combined merger adjustments represent operating cost reductions primarily related to the implementation of strategic actions and initiatives related to the business combination completed on July 12, 2017.


 
   Exela Technologies
Schedule 6: Further Adjusted EBITDA Reconciliation – 2017
($ in millions)     
As Reported
FY 2017 
 Novitex
(Jan 1 – Jul 12)(1)
 Pro Forma
FY 2017
Net loss($204.3) ($38.1) ($242.4)
Taxes  (60.2)   (6.9)   (67.2)
Interest expense  128.5   24.9   153.4
Depreciation and amortization  98.9   20.6   119.5
EBITDA($37.2) $0.5 ($36.7)
Impairment of goodwill and other intangible assets  69.4   -    69.4
(Gain) / loss on extinguishment of debt  35.5   17.5   53.0
Optimization and restructuring expenses  42.5   5.4   47.9
Transaction and integration costs  88.9   10.0   99.0
Non-cash charges  6.7   -    6.7
New contract setup  -    2.0   2.0
Oversight and management Fees  4.2   1.0   5.1
(Gain) / loss on derivative instruments  (1.3)   -    (1.3)
Adjusted EBITDA$208.8 $36.4 $245.2
Gain / (loss) on currency exchange  2.3   0.1   2.4
Combined merger adjustments      99.2
Further Adjusted EBITDA    $346.8
      
 (1Represents financial performance of Novitex for a year-to-date period ending on the transaction closing date of July 12, 2017.

Note: - Net loss for the period January 1- July 12 is presented on the basis of the previous debt structure at the respective standalone companies. As of July 12th, the existing debt structures at respective Exela entities have been replaced with a new capital structure consisting of $350 Million Term Loan and $1.0 Billion Senior Secured Notes.
-Combined merger adjustments represent operating cost reductions primarily related to the implementation of strategic actions and initiatives related to the business combination completed on July 12, 2017. 


 
 Exela Technologies
Schedule 7: Pro Forma Revenue and Capital Expenditures – 2016 and 2017
    
($ in millions)   
As Reported(1)NovitexPro Forma
Revenue - FY 2017$1,152.3$304.0$1,456.3
Revenue - FY 2016$789.9$543.2$1,333.1
    
Revenue - Q3 2017$338.4$19.8$358.2
Revenue - Q4 2016$212.4$140.1$352.5
    
    
Capital expenditures - FY 2017$33.3$9.1$42.4
Capital expenditures - FY 2016$35.6$15.9$51.5
    
Capital expenditures - Q4 2016$12.4$3.0$15.4
    
    
    
(1) Financial results for FY 2016 does not include contribution for the first nine months from the TransCentra acquisition which closed on September 28, 2016. 


 
Exela Technologies
Schedule 8: Pro Forma Selling, general and administrative expenses (Incl. related party) – 2016 and 2017
 
Selling, general and administrative expenses (Incl related party)    
     
($ in millions)Q4 2016Q4 2017 FY 2016FY 2017
As Reported    
Selling, general and administrative expenses   35.1  48.3  130.4  221.0
Related party expense  3.1  1.7  10.5  33.4
Total  38.2  50.0  140.9  254.4
     
Novitex    
Selling, general and administrative expenses   11.8   49.8  34.8
Related party expense    0.1  0.3
Total  11.8   49.9  35.1
     
Pro forma    
Selling, general and administrative expenses   46.8  48.3  180.2  255.8
Related party expense  3.1  1.7  10.6  33.7
Total  49.9  50.0  190.8  289.5
     


Contact: Jim Mathias
E: ir@exelatech.com
W: investors.exelatech.com
T: 972-821-5808